$19.53 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of June 2023 : $0.67 B

According to BeiGene 's latest financial reports the company's total debt is $0.67 B. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2023)

Total debt by year

Year Total debt Change
2022-12-31$0.53 B-22.53%
2021-12-31$0.69 B23.61%
2020-12-31$0.56 B102.62%
2019-12-31$0.27 B39.79%
2018-12-31$0.19 B20.45%
2017-12-31$0.16 B852.99%
2016-12-31$17.28 M-16.85%
2015-12-31$20.78 M50.21%
2014-12-31$13.83 M-49.43%
2013-12-31$27.36 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
$0.29 B-56.38%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA